在缺血性中风中XIII因子的作用:一个促进血栓稳定和抵抗溶解的关键分子
Juan Marta-Enguita1, Manuel Navarro-Oviedo2, Florencio J D M Machado2
1Atherothrombosis Laboratory, Cardiovascular Diseases Program, Centro de Investigacion Medica Aplicada (CIMA), Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona Spain; Neurology Department, Hospital Universitario Navarra, Pamplona, Spain; Red de Investigación Cooperativa Orientada a Resultados en Salud (RICORS)-Ictus Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Electronic address: https://twitter.com/jmartaen.
Journal of thrombosis and haemostasis : JTH
|December 31, 2023
概括
在小鼠模型中,抑制凝血因子XIII (FXIII) 降低了中风损伤和改善了血块溶解. 在缺血性中风患者中,FXIIIa在稳定血块和抵抗溶解方面发挥着关键作用.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 神经学 神经学
背景情况:
- 凝血因子XIII (FXIII) 对于凝血的稳定性和溶解至关重要.
- 激活的FXIII (FXIIIa) 交叉链纤维素和其他静血因子.
研究的目的:
- 在缺血性中风 (IS) 的小鼠模型中研究FXIII抑制的治疗潜力.
- 阐明FXIIIa在IS患者血栓形成和溶解中的作用.
主要方法:
- 在小鼠中使用铁化物诱导的缺血性中风模型,使用或不使用FXIIIa抑制剂.
- 血栓形成显微镜评估了人类和小鼠血液中的血栓特性.
- 使用纤维素板和患者样本研究了依赖FXIIIa的纤维素交联和溶解.
- 在85名IS患者中测量了循环和血栓FXIIIa水平.
主要成果:
- 在小鼠中,FXIII抑制降低了心脏病发作的大小,微血栓,并改善了运动功能,而不会引起出血.
- 脑卒中后的FXIII封锁也减轻了大脑损伤和神经系统缺陷.
- 通过FXIII抑制,延迟了凝块的形成,减少了度,并通过组织等离子体激活剂增强了溶解.
- 通过FXIIIa介导的交叉连接增加了纤维素密度和溶解抵抗,特别是与α2-抗等离子素 (α2AP).
- 在IS患者中,血栓FXIII和α2AP与炎症和静血标志物相关;血FXIIIa与血栓α2AP和纤维素相关.
结论:
- 在血栓稳定,α2AP交联和溶解抵抗方面,FXIIIa是关键的.
- FXIII抑制在实验性缺血性中风中表现出保护作用.
- 针对FXIIIa可能为缺血性中风提供治疗策略.
相关概念视频
01:16Clot Retraction and Fibrinolysis
6.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
702
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
702
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.8K
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
01:22Formation of the Platelet Plug
6.3K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.3K
01:09Coagulation
6.7K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.7K